Shenzhen Salubris Pharmaceuticals Co Ltd Market Cap ($5.14 Billion)
Market Cap & Net Worth: Shenzhen Salubris Pharmaceuticals Co Ltd (002294)
Shenzhen Salubris Pharmaceuticals Co Ltd market cap. Shenzhen Salubris Pharmaceuticals Co Ltd (SHE:002294) has a market capitalization of $5.14 Billion (CN¥35.12 Billion) as of November 5, 2026. Listed on the SHE stock exchange, this China-based company holds position #3422 globally and #431 in its home market, demonstrating a 3.52% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shenzhen Salubris Pharmaceuticals Co Ltd's stock price CN¥31.50 by its total outstanding shares 1114816535 (1.11 Billion). Also see Shenzhen Salubris Pharmaceuticals Co Ltd cash conversion from operations for how efficiently the company converts equity into cash flow.
Shenzhen Salubris Pharmaceuticals Co Ltd Market Cap History (2015–2026)
Shenzhen Salubris Pharmaceuticals Co Ltd market cap history from 2015 to 2026. Data shows growth from $4.14 Billion to $5.14 Billion (2.75% CAGR). Check latest Shenzhen Salubris Pharmaceuticals Co Ltd stock price today for real-time trading data and today's change.
Shenzhen Salubris Pharmaceuticals Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shenzhen Salubris Pharmaceuticals Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore 002294 shareholders equity momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.26x
Shenzhen Salubris Pharmaceuticals Co Ltd's market cap is 1.26 times its annual revenue
Latest Price to Earnings (P/E) Ratio
8.39x
Shenzhen Salubris Pharmaceuticals Co Ltd's market cap is 8.39 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $4.14 Billion | $3.48 Billion | $1.27 Billion | 1.19x | 3.27x |
| 2016 | $4.11 Billion | $3.83 Billion | $1.40 Billion | 1.07x | 2.94x |
| 2017 | $6.50 Billion | $4.15 Billion | $1.45 Billion | 1.56x | 4.48x |
| 2018 | $3.06 Billion | $4.65 Billion | $1.46 Billion | 0.66x | 2.10x |
| 2019 | $3.01 Billion | $4.47 Billion | $715.20 Million | 0.67x | 4.21x |
| 2020 | $4.39 Billion | $2.74 Billion | $60.86 Million | 1.60x | 72.17x |
| 2021 | $4.24 Billion | $3.06 Billion | $533.73 Million | 1.39x | 7.94x |
| 2022 | $5.19 Billion | $3.48 Billion | $637.09 Million | 1.49x | 8.15x |
| 2023 | $5.23 Billion | $3.37 Billion | $580.07 Million | 1.55x | 9.02x |
| 2024 | $5.05 Billion | $4.01 Billion | $601.57 Million | 1.26x | 8.39x |
Competitor Companies of 002294 by Market Capitalization
Companies near Shenzhen Salubris Pharmaceuticals Co Ltd in the global market cap rankings as of November 5, 2026. Also see Shenzhen Salubris Pharmaceuticals Co Ltd (002294) total assets for a full breakdown of the balance sheet.
Key companies related to Shenzhen Salubris Pharmaceuticals Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #514 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #538 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #588 globally with a market cap of $45.79 Billion USD ( CN¥312.89 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #621 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #514 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #538 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $47.80 |
| #588 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.79 Billion | CN¥49.05 |
| #621 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.50 |
Market Capitalization of Shenzhen Salubris Pharmaceuticals Co Ltd (2015–2026)
Market capitalization of Shenzhen Salubris Pharmaceuticals Co Ltd from 2015 to today. Between 2015 and today, Shenzhen Salubris Pharmaceuticals Co Ltd's market cap moved from $4.14 Billion to $ 5.14 Billion, with a yearly change of 2.75%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CN¥5.14 Billion | -36.43% |
| 2025 | CN¥8.08 Billion | +60.20% |
| 2024 | CN¥5.05 Billion | -3.57% |
| 2023 | CN¥5.23 Billion | +0.82% |
| 2022 | CN¥5.19 Billion | +22.52% |
| 2021 | CN¥4.24 Billion | -3.56% |
| 2020 | CN¥4.39 Billion | +45.79% |
| 2019 | CN¥3.01 Billion | -1.65% |
| 2018 | CN¥3.06 Billion | -52.86% |
| 2017 | CN¥6.50 Billion | +58.26% |
| 2016 | CN¥4.11 Billion | -0.77% |
| 2015 | CN¥4.14 Billion | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Shenzhen Salubris Pharmaceuticals Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $5.14 Billion USD |
| MoneyControl | $5.14 Billion USD |
| MarketWatch | $5.14 Billion USD |
| marketcap.company | $5.14 Billion USD |
| Reuters | $5.14 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Shenzhen Salubris Pharmaceuticals Co Ltd
Shenzhen Salubris Pharmaceuticals Co., Ltd. engages in the research, development, production, and sale of medicines and medical devices in China. The company offers drugs for various therapeutic fields, such as thrombosis, hypertension and related diseases, osteoporosis, and infections, as well as anti-osteolysis, antiallergic, antiepileptic, and antidepressant medicines. It also develops Sacubit… Read more